2010
DOI: 10.1016/j.yjmcc.2009.11.012
|View full text |Cite
|
Sign up to set email alerts
|

Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
59
0
4

Year Published

2011
2011
2024
2024

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 61 publications
(66 citation statements)
references
References 92 publications
(122 reference statements)
3
59
0
4
Order By: Relevance
“…2A–C), consistent with a defect in diastolic function. The mitral deceleration time did not change (Table 3), and the mRNA expression of SERCA (sarco/endoplasmic reticulum calcium ATPase) and its phospholambin regulator (PLN), which are frequently, but not invariably [28, 29], diminished with diastolic dysfunction, were not altered in Acsl1 H−/− mice before or after rapamycin treatment (SERCA1/2: vehicle control, 1.11±0.24; rapamycin control, 1.41±0.35; vehicle Acsl1 H−/− , 0.83±0.09; rapamycin Acsl1 H−/− , 1.16±0.15; PLN: vehicle control, 1.11±0.0.21; rapamycin control, 1.33±0.25; vehicle Acsl1 H−/− , 0.85±0.09; rapamycin Acsl1 H−/− , 1.23±0.14; n=5–6). Because the 10 week rapamycin treatment itself induced diastolic dysfunction in both control and Acsl1 deficient mice, as previously described [3032], it was not possible to interpret the effects of Acsl1-related mTOR activity on diastolic function.…”
Section: Resultsmentioning
confidence: 99%
“…2A–C), consistent with a defect in diastolic function. The mitral deceleration time did not change (Table 3), and the mRNA expression of SERCA (sarco/endoplasmic reticulum calcium ATPase) and its phospholambin regulator (PLN), which are frequently, but not invariably [28, 29], diminished with diastolic dysfunction, were not altered in Acsl1 H−/− mice before or after rapamycin treatment (SERCA1/2: vehicle control, 1.11±0.24; rapamycin control, 1.41±0.35; vehicle Acsl1 H−/− , 0.83±0.09; rapamycin Acsl1 H−/− , 1.16±0.15; PLN: vehicle control, 1.11±0.0.21; rapamycin control, 1.33±0.25; vehicle Acsl1 H−/− , 0.85±0.09; rapamycin Acsl1 H−/− , 1.23±0.14; n=5–6). Because the 10 week rapamycin treatment itself induced diastolic dysfunction in both control and Acsl1 deficient mice, as previously described [3032], it was not possible to interpret the effects of Acsl1-related mTOR activity on diastolic function.…”
Section: Resultsmentioning
confidence: 99%
“…It acts as a Ca 2þ -ATPase that transfers Ca 2þ from the cytosol to the lumen of the sarcoplasmic reticulum at the expense of ATP hydrolysis during muscle relaxation (28). As one of the family members, SERCA2 is known as an important regulator of normal calcium homeostasis and signaling (29,30). Alterations in calcium-dependent signaling are involved in cell proliferation and differentiation, apoptosis, and disruption of calcium homeostasis, which may contribute to cancer development.…”
Section: Discussionmentioning
confidence: 99%
“…The third member of the SERCA family, SERCA3 bears approximately 80% homology with other SERCA isoforms [37,41]. The ATP2A3 gene can give rise to six known SERCA3 isoforms that arise by alternative splicing in the 3’ region of the transcripts [39,42,43]. Comparative analysis of the localization and of the biochemical characteristics of various SERCA isoforms revealed significant differences.…”
Section: The Serca Multigene Family Co-expression Of Serca2 and Smentioning
confidence: 99%